公开(公告)号：EP2893343A4

公开(公告)日：2016-08-31

申请号：EP13835859

申请日：2013-09-06

申请人： UNIV ALBERTA ,  HANNOVER MED HOCHSCHULE

发明人： LANDI ABDOLAMIR ,  HOUGHTON MICHAEL ,  TYRRELL LORNE D ,  LANKISCH TIM ,  WEISMUELLER TOBIAS ,  MANNS MICHAEL

IPC分类号： G01N33/48 ,  G06F19/00

CPC分类号： G01N33/6893 ,  A61K45/00 ,  G01N33/6827 ,  G01N2333/521 ,  G01N2333/523 ,  G01N2333/5443 ,  G01N2333/916 ,  G01N2800/085 ,  G06F19/24 ,  G06F19/3431 ,  G06F19/345 ,  G16H50/20 ,  G16H50/30 ,  Y02A90/22 ,  Y02A90/24 ,  Y02A90/26

摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

摘要翻译： 本公开提供了用于促进受试者中炎性肝病诊断的方法和组合物。 方法和组合物通常涉及单独或与嗜酸细胞活化趋化因子-1（E1）的水平以及任选地与CCL22水平以及进一步任选的IL15水平检测嗜酸细胞活化趋化因子-3（E3）水平。 这些水平可以用于促进自身免疫性肝炎（AIH），原发性胆汁性肝硬化（PBC）和原发性硬化性胆管炎（PSC）中的至少一种的肝脏疾病的诊断，和/或促进AIH， PBC和PSC。 本公开的方法和组合物也用于促进受试者的治疗决定。